California State Teachers Retirement System Raises Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

California State Teachers Retirement System increased its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 30.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 231,535 shares of the company's stock after acquiring an additional 54,449 shares during the quarter. California State Teachers Retirement System owned about 0.06% of Recursion Pharmaceuticals worth $1,565,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at $128,000. Integrated Advisors Network LLC boosted its stake in Recursion Pharmaceuticals by 36.8% during the fourth quarter. Integrated Advisors Network LLC now owns 17,588 shares of the company's stock worth $119,000 after buying an additional 4,731 shares during the period. GF Fund Management CO. LTD. purchased a new position in Recursion Pharmaceuticals during the fourth quarter worth about $54,000. CSS LLC IL acquired a new stake in shares of Recursion Pharmaceuticals during the fourth quarter valued at about $366,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Recursion Pharmaceuticals by 5.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,259,178 shares of the company's stock valued at $15,272,000 after acquiring an additional 118,428 shares during the period. Hedge funds and other institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ RXRX traded down $0.23 during trading on Thursday, reaching $5.17. The company had a trading volume of 28,161,394 shares, compared to its average volume of 14,815,788. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $2.10 billion, a PE ratio of -3.38 and a beta of 0.84. Recursion Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $12.36. The stock has a 50-day moving average price of $4.85 and a two-hundred day moving average price of $6.34.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). The firm had revenue of $14.75 million during the quarter, compared to analysts' expectations of $18.12 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals's revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter last year, the company posted ($0.39) earnings per share. As a group, sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

RXRX has been the topic of a number of recent research reports. Needham & Company LLC cut their price target on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Leerink Partners cut their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research note on Friday, February 28th. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Finally, Morgan Stanley lowered their price objective on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $7.60.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.